Virax Biolabs Group Ltd
Company Profile
Business description
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.
Contact
Bo’Ness Road Newhouse
BioCity Glasgow
Lanarkshire
MotherwellML1 5UH
GBRT: +44 2077887414
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2027
Employees
26
Stocks News & Analysis
stocks
ASX rare earths play looks to expand production
stocks
Anthropic’s leaked financials reflect fast growth, but not a $2 trillion valuation
stocks
The 10 best US companies to invest in now
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,903.50 | 44.30 | 0.50% |
| CAC 40 | 7,876.89 | 42.79 | 0.55% |
| DAX 40 | 25,408.24 | 154.03 | 0.61% |
| Dow JONES (US) | 51,267.90 | 90.94 | 0.18% |
| FTSE 100 | 10,540.10 | 42.16 | 0.40% |
| HKSE | 24,280.56 | 240.22 | 1.00% |
| NASDAQ | 27,477.31 | 286.45 | 1.05% |
| Nikkei 225 | 70,683.98 | 737.12 | 1.05% |
| NZX 50 Index | 13,700.12 | 1.10 | 0.01% |
| S&P 500 | 7,773.95 | 51.23 | 0.66% |
| S&P/ASX 200 | 8,735.70 | 49.30 | 0.57% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |